297 related articles for article (PubMed ID: 24196788)
21. The prognostic benefit of tumour-infiltrating Natural Killer cells in endometrial cancer is dependent on concurrent overexpression of Human Leucocyte Antigen-E in the tumour microenvironment.
Versluis MAC; Marchal S; Plat A; de Bock GH; van Hall T; de Bruyn M; Hollema H; Nijman HW
Eur J Cancer; 2017 Nov; 86():285-295. PubMed ID: 29059634
[TBL] [Abstract][Full Text] [Related]
22. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
[TBL] [Abstract][Full Text] [Related]
23. The non-classical antigens of HLA-G and HLA-E as diagnostic and prognostic biomarkers and as therapeutic targets in transplantation and tumors.
Seliger B
Clin Transpl; 2013; ():465-72. PubMed ID: 25095542
[TBL] [Abstract][Full Text] [Related]
24. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
[TBL] [Abstract][Full Text] [Related]
25. A Critical Assessment of the Association between HLA-G Expression by Carcinomas and Clinical Outcome.
van de Water RB; Krijgsman D; Houvast RD; Vahrmeijer AL; Kuppen PJK
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34361031
[TBL] [Abstract][Full Text] [Related]
26. Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.
Donada M; Bonin S; Barbazza R; Pettirosso D; Stanta G
BMC Gastroenterol; 2013 Feb; 13():36. PubMed ID: 23446022
[TBL] [Abstract][Full Text] [Related]
27. HLA-G regulators in cancer medicine: an outline of key requirements.
Zidi I; Ben Amor N
Tumour Biol; 2011 Dec; 32(6):1071-86. PubMed ID: 21792710
[TBL] [Abstract][Full Text] [Related]
28. The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials.
Cascinu S; Poli D; Zaniboni A; Lonardi S; Labianca R; Sobrero A; Rosati G; Di Bartolomeo M; Scartozzi M; Zagonel V; Pella N; Banzi M; Torri V
Eur J Cancer; 2019 Apr; 111():1-7. PubMed ID: 30797014
[TBL] [Abstract][Full Text] [Related]
29. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G
Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of HLA class I expression in patients with colorectal cancer.
Iwayama Y; Tsuruma T; Mizuguchi T; Furuhata T; Toyota N; Matsumura M; Torigoe T; Sato N; Hirata K
World J Surg Oncol; 2015 Feb; 13():36. PubMed ID: 25889416
[TBL] [Abstract][Full Text] [Related]
31. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells.
Levy EM; Sycz G; Arriaga JM; Barrio MM; von Euw EM; Morales SB; González M; Mordoh J; Bianchini M
Innate Immun; 2009 Apr; 15(2):91-100. PubMed ID: 19318419
[TBL] [Abstract][Full Text] [Related]
32. Tumor mutational load, CD8
Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
[TBL] [Abstract][Full Text] [Related]
33. A method for semi-automated image analysis of HLA class I tumour epithelium expression in rectal cancer.
Krijgsman D; Van Vlierberghe RLP; Evangelou V; Vahrmeijer AL; Van de Velde CJH; Sier CFM; Kuppen PJK
Eur J Histochem; 2019 May; 63(2):. PubMed ID: 31113192
[TBL] [Abstract][Full Text] [Related]
34. An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma.
Vora AR; Rodgers S; Parker AJ; Start R; Rees RC; Murray AK
Br J Cancer; 1997; 76(7):836-44. PubMed ID: 9328140
[TBL] [Abstract][Full Text] [Related]
35. Expression of MHC class I and class II antigens in colonic carcinomas.
Norazmi M; Hohmann AW; Skinner JM; Bradley J
Pathology; 1989 Oct; 21(4):248-53. PubMed ID: 2633113
[TBL] [Abstract][Full Text] [Related]
36. The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.
Talebian Yazdi M; van Riet S; van Schadewijk A; Fiocco M; van Hall T; Taube C; Hiemstra PS; van der Burg SH
Oncotarget; 2016 Jan; 7(3):3477-88. PubMed ID: 26658106
[TBL] [Abstract][Full Text] [Related]
37. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer.
Madjd Z; Spendlove I; Pinder SE; Ellis IO; Durrant LG
Int J Cancer; 2005 Nov; 117(2):248-55. PubMed ID: 15900607
[TBL] [Abstract][Full Text] [Related]
38. Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma.
Kloth JN; Gorter A; Fleuren GJ; Oosting J; Uljee S; ter Haar N; Dreef EJ; Kenter GG; Jordanova ES
J Pathol; 2008 Jul; 215(3):222-30. PubMed ID: 18438953
[TBL] [Abstract][Full Text] [Related]
39. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
Niedzwiecki D; Hasson RM; Lenz HJ; Ye C; Redston M; Ogino S; Fuchs CS; Compton CC; Mayer RJ; Goldberg RM; Colacchio TA; Saltz LB; Warren RS; Bertagnolli MM
Oncologist; 2017 Jan; 22(1):107-114. PubMed ID: 27821793
[TBL] [Abstract][Full Text] [Related]
40. HLA non-A,B,C class I genes: their structure and expression.
Heinrichs H; Orr HT
Immunol Res; 1990; 9(4):265-74. PubMed ID: 2089074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
